No Data
KINGWORLD: ANNUAL REPORT 2024
KINGWORLD (01110.HK) adopts the 2025 share incentive plan.
On April 14, 2023, Gelonghui reported that KINGWORLD (01110.HK) announced that due to the 2019 share award plan is expected to expire in August 2025, the Board of Directors is pleased to announce that it has adopted the 2025 share award plan on April 14, 2025, and terminated the 2019 share award plan to reflect the latest changes and regulations of Chapter 17 of the listing rules. The 2021 stock option plan was approved by the Shareholders on August 20, 2021. Under the 2021 stock option plan, the directors are authorized to grant options to several eligible participants (including any executive directors of the Group.
There's No Escaping Kingworld Medicines Group Limited's (HKG:1110) Muted Earnings Despite A 26% Share Price Rise
Jinhuo Medicine (1110.HK): Seizing the opportunities of the times and embarking on a new journey.
In 2024, driven by the dual forces of the restructuring of the Global pharmaceutical supply chain and the transformation of the domestic population structure, the Industry is undergoing a fundamental shift from scale-driven to value-driven empowerment. Coinciding with the national drug regulatory authority's implementation of the strategic deployment of the "South China Greater Bay Area Concept Development Plan," an innovative policy has been launched to simplify the approval process for Traditional Chinese Medicine that has already been approved in Hong Kong and Macao (planned to be fully implemented in January 2025). This groundbreaking measure not only marks a new stage of institutional openness for the Traditional Chinese Medicine industry in the Greater Bay Area but also creates an unprecedented policy support system for deep collaboration and innovation in Traditional Chinese Medicine between Hong Kong and Shenzhen.
Kingworld Medicines Group Ltd. Declares Final Cash Dividend for 2024
Express News | Kingworld Medicines Group FY Revenue RMB 715,700 Million
